Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02622386 · ClinicalTrials.gov registry record · Phase 2
The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT02622386 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 23 participants.
The verdict
NCT02622386, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms. Amongst patients with skin disease, there is significant interest in using complementary alternative medicine and vitamins to treat their disease. Previous human case reports suggest that riboflavin, commonly known as Vitamin B2, is clinically effective for the treatment of psoriasis; however, they were not conclusive. More recent human trials have shown that 400 mg of daily oral riboflavin is a safe and well-tolerated medication to administer to humans. For the purpose of this study, the riboflavin is used as an investigational drug.
Interventions
- OTHER Placebo
- DRUG Riboflavin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-08-11 |
| Est. Completion | 2020-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02622386
The ClinicalTrials.gov registry entry for NCT02622386 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02622386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02622386 about?
NCT02622386 is a clinical study titled "The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis". The purpose of this study is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients...
What is the current status of trial NCT02622386?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2016-08-11. Estimated completion is 2020-04-06.
What interventions are being tested in trial NCT02622386?
The interventions under investigation include: Placebo (OTHER), Riboflavin (DRUG).
Who is sponsoring clinical trial NCT02622386?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.